A case report of a patient with hereditary hemorrhagic telangiectasia treated successively with thalidomide and bevacizumab

Case Reports in Oncology

Volumn 3, Issue 3, 2010, Pages 463-470

  Amanzada, Ahmad ^a   Töppler, Gwen Jana ^a   Cameron, Silke ^a   Schwörer, Harald ^a   Ramadori, Giuliano ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Bevacizumab; Hereditary hemorrhagic telangiectasia; Thalidomide

Indexed keywords

BECLOMETASONE DIPROPIONATE; BEVACIZUMAB; THALIDOMIDE; THYROXINE; TIOTROPIUM BROMIDE;

ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; DRUG WITHDRAWAL; ERYTHROCYTE CONCENTRATE; HUMAN; IMMUNOTHERAPY; LUNG DISEASE; MALE; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE; SYMPTOM;

EID: 78751511656     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000323152     Document Type: Article

References (34)

1. Guttmacher AE, Marchuk DA, White RI Jr: Hereditary hemorrhagic telangiectasia. N Engl J Med 1995;333:918-924.
2. Garcia-Tsao G: Liver involvement in hereditary hemorrhagic telangiectasia. J Hepatol 2007;46:499-507.
3. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD, Plauchu H: Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000;91:66-67.
4. Haitjema T, Westermann CJJ, Overtoom TTC, Timmer R, Disch F, et al: Hereditary hemorrhagic teleangiectasia (Osler-Weber-Rendu-disease): new insights in pathogenesis, complications, and treatment. Arch Intern Med 1996;156:714-719.
5. Reilly PJ, Nostrant TT: Clinical manifestations of hereditary hemorrhagic telangiectasia. Am J Gastroenterol 1984;79:363-367.
6. McDonald JE, Miller FJ, Hallam SE, Nelson L, Marchuk DA, Ward KJ: Clinical manifestations in a large hereditary hemorrhagic telangiectasia (HHT) type 2 kindred. Am J Med Genet 2000;93:320-327.
7. Plauchu H, de Chadarevian JP, Bideau A, Robert JM: Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989;32:291-297.
8. Garcia-Tsao G, Korzenik JR, Young L, Henderson KJ, Jain D, et al: Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2000;343:931-936.
9. Matsubara S, Mandzia JL, ter Brugge K, Willinsky RA, Faughnan ME: Angiographic and clinical characteristics of patients with cerebral arteriovenous malformations associated with hereditary hemorrhagic telangiectasia. AJNR Am J Neuroradiol 2000;21:1016-1020.
10. McAllister KA, Grogg KM, Johnson DW, et al: Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994;8:345-351.
11. Johnson DW, Berg JN, Baldwin MA, et al: Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996;13:189-195.
12. Cole SG, Begbie ME, Wallace GM, Shovlin CL: A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 2005;42:577-582.
13. Sadick H, Riedel F, Naim R, Goessler U, H?mann K, Hafner M, Lux A: Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 2005;90:818-828.
14. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 1994;91:4082-4085.
15. Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N: Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci 2009;106:8573-8578.
16. Bauditz J, Lochs H: Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding. World J Gastroenterol 2007;13:5979-5984.
17. Bauditz J, Schachschal G, Wedel S, Lochs H: Thalidomide for treatment of severe intestinal bleeding. Gut 2004;53:609-612.
18. Dabak V, Kuriakose P, Kamboj G, Shurafa M: A pilot study of thalidomide in recurrent GI bleeding due to angiodysplasias. Dig Dis Sci 2008;53:1632-1635.
19. Kamalaporn P, et al: Thalidomide for the treatment of chronic gastrointestinal bleeding from angiodysplasias: a case series. Eur J Gastroenterol Hepatol 2009;21:1347-1350.
20. Kurstin R: Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease. Oncology 2002;16:21-24.
21. Pérez-Encinas M, Rabunal Martinez MJ, Bello Lopez JL: Is thalidomide effective for the treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectasia? Haematologica 2002;87:ELT34.
22. Melchert M, List A: The thalidomide saga. Int J Biochem Cell Biol 2007;39:1489-1499.
23. Flieger D, Hainke S, Fischbach W: Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 2006;85:631-632.
24. Bose P, Holter JL, Selby GB: Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009;360:2143-2144.
25. Oosting S, Nagengast W, de Vries E: More on bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009;361:931.
26. Davidson TM, Olitsky SE, Wei LL: Hereditary hemorrhagic telangiectasia/avastin. Laryngoscope 2010;120:432-435.
27. Mitchell A, Adams LA, MacQuillan G, Tibballs J, vanden Driesen R, Delriviere L: Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl 2008;14:210-213.
28. Richmon JD, Tian Y, Husseman J, Davidson TM: Use of a sprayed fibrin hemostatic sealant after laser therapy for hereditary hemorrhagic telangiectasia epistaxis. Am J Rhinol 2007;21:187-191.
29. Harvey RJ, Kanagalingam J, Lund VJ: The impact of septodermoplasty and potassium-titanyl-phosphate (KTP) laser therapy in the treatment of hereditary hemorrhagic telangiectasia-related epistaxis. Am J Rhinol 2008;22:182-187.
30. Lund VJ, Howard DJ: Closure of the nasal cavities in the treatment of refractory hereditary haemorrhagic telangiectasia. J Laryngol Otol 1997;111:30-33.
31. Flessa HC, Glueck HI: Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): management of epistaxis in nine patients using systemic hormone therapy. Arch Otolaryngol 1977;103:148-151.
32. van Cutsem E, Rutgeerts P, Vantrappen G: Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet 1990;335:953-955.
33. Shovlin CL, Letarte M: Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999;54:714-729.
34. Lerut J, Orlando G, Adam R, Sabbàbull;C, Pfitzmann R, Klempnauer J, et al: Liver transplantation for hereditary hemorrhagic telangiectasia: report of the European liver transplant registry. Ann Surg 2006;244:854-864.